<p>a) Caspase 3/7 activity was evaluated in ACHN cells treated with Sorafenib for 24 hours. b) Viability of ACHN cells was evaluated under the same conditions by MTT assay. c) ACHN cells were exposed to 10 μM Sorafenib for 16 hours. Protein extracts were blotted with the indicated antibodies. d) Caspase 3/7 activity was evaluated in 786-O cells treated with Sorafenib for 24 hours. e) Viability of 786-O cells was evaluated by MTT assay as in B). f) 786-O cells were exposed to 10 μM Sorafenib for 16 hours. Protein extracts were blotted with the indicated antibodies. Tubulin was used as a loading control.</p
<p>SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 cells were treated with sorafenib (10 µM) for 48 hours. ...
<p>(A) The expression of E-cadherin was increased, and the expression of a-SMA was decreased in the ...
<p>(<b>A</b>) To assess the effects of sorafenib, cells were exposed for 2 hours to control vehicle ...
<p>a)ACHN cells were treated with Sorafenib at the indicated concentrations in the presence or absen...
<p>a) ACHN cells were treated with MK-2206 at the indicated concentrations (μM) for 24 hours and cas...
<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
<p>a) ACHN and 786-O cells were treated for 48 h at the indicated concentrations of Sorafenib and vi...
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepa...
INTRODUCTION: Desmoid-type fibromatosis (DTF) is a rare, soft tissue tumour. Sorafenib, a multikinas...
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepa...
OBJECTIVES:To fully clarify the role of Mitogen Activated Protein Kinase in the therapeutic response...
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and pr...
Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mech...
<div><p>Objectives</p><p>To fully clarify the role of Mitogen Activated Protein Kinase in the therap...
<p>SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 cells were treated with sorafenib (10 µM) for 48 hours. ...
<p>(A) The expression of E-cadherin was increased, and the expression of a-SMA was decreased in the ...
<p>(<b>A</b>) To assess the effects of sorafenib, cells were exposed for 2 hours to control vehicle ...
<p>a)ACHN cells were treated with Sorafenib at the indicated concentrations in the presence or absen...
<p>a) ACHN cells were treated with MK-2206 at the indicated concentrations (μM) for 24 hours and cas...
<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
<p>a) ACHN and 786-O cells were treated for 48 h at the indicated concentrations of Sorafenib and vi...
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepa...
INTRODUCTION: Desmoid-type fibromatosis (DTF) is a rare, soft tissue tumour. Sorafenib, a multikinas...
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepa...
OBJECTIVES:To fully clarify the role of Mitogen Activated Protein Kinase in the therapeutic response...
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and pr...
Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mech...
<div><p>Objectives</p><p>To fully clarify the role of Mitogen Activated Protein Kinase in the therap...
<p>SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 cells were treated with sorafenib (10 µM) for 48 hours. ...
<p>(A) The expression of E-cadherin was increased, and the expression of a-SMA was decreased in the ...
<p>(<b>A</b>) To assess the effects of sorafenib, cells were exposed for 2 hours to control vehicle ...